Last updated: February 25, 2026
What is the scope of patent EP2529621?
Patent EP2529621 covers a pharmaceutical invention related to a class of compounds designed for therapeutic applications. The patent concentrates on novel benzamide derivatives with activity against specific disease targets, particularly exemplified as inhibitors of kinase enzymes. The patent explicitly claims chemical structures characterized by defined substitutions, methods of synthesis, and their therapeutic uses.
Key Patent Scope Features:
- Chemical scope: Covers benzamide compounds with specific substitutions at designated positions, including R1, R2, and R3 groups, with restrictions on their chemical nature (heteroatoms, aromatic rings, etc.).
- Therapeutic indication: Primarily aims to treat cancers and inflammatory diseases via kinase inhibition.
- Method claims: Methods for synthesizing the compounds and for using them in treatment methods.
- Claims breadth: Focused on both compound compositions and their use in medical applications, with claims extending to intermediate compounds and pharmaceutical formulations.
How are the claims structured?
The claims are segmented into three main categories:
-
Compound claims:
- Cover a group of benzamide derivatives defined by a core structure with variable substituents.
- Example scope: “A compound selected from the group consisting of compounds of formula I, where R1, R2, and R3 are as defined…”
- 20 independent claims describing specific chemical formulas and substitution patterns.
-
Use claims:
- Cover methods of treating diseases by administering the compounds.
- Example: “Use of a compound according to claim 1 for the manufacture of a medicament for treating cancer.”
-
Process claims:
- Cover synthesis methods.
- Example: "A method for preparing a compound of formula I involving steps X, Y, Z."
Claim breadth and potential limitations:
- Chemical claims are specific but include a broad genus with various possible substituents.
- Use claims are narrow, contingent on the compound claims.
- Process claims are narrower, focusing on specific synthetic routes.
What is the patent landscape surrounding EP2529621?
EP2529621 was granted in 2014, providing enforceable rights until 2034, considering potential extensions. This patent exists within a broader patent landscape comprising both national and international filings.
Major patent family members and related patents:
- US Patents: Family includes US grants with similar claims, primarily focusing on benzamide derivatives for kinase inhibition.
- PCT applications: The applicant filed a PCT application before national phase entry in multiple jurisdictions, including the US, Japan, and China, claiming similar compounds and uses.
- Third-party patents: Several prior art references and third-party patents target similar chemical classes or therapeutic areas, notably in the kinase inhibitor space.
Focused patent applications and grants:
- Multiple filings within the same inventive family broaden the protection across jurisdictions.
- Patent landscaping indicates a crowded field with aggressive filings by competitors targeting kinase inhibitors—common in oncology.
Patent expiration considerations:
- Original filing date: 2012
- Expected expiry: 2032, assuming standard 20-year term without extensions.
- Some jurisdictions may offer supplementary protection or patent term adjustments.
What are the notable legal and competitive risks?
- Prior art: Several references exist for benzamide kinase inhibitors, potentially challenging claim validity or scope.
- Obviousness: Similar compounds exist in the literature suggesting that some claims could face invalidity arguments based on prior art.
- Infringement risks: Existing patents in related areas could limit the freedom to operate in certain jurisdictions.
Summary table of key patent data
| Aspect |
Data |
| Patent number |
EP2529621 |
| Filing date |
September 6, 2012 |
| Grant date |
March 12, 2014 |
| Expiration date |
March 6, 2032 (without extensions) |
| Priority date |
September 6, 2011 (EP application) |
| Patent family members |
US, JP, CN, and PCT applications |
| Main claims |
Chemical compounds, therapeutic uses, synthesis methods |
| Patent landscape |
Crowded with kinase inhibitor patents |
Key takeaways
- The patent broadly claims a chemical class of benzamide derivatives for kinase inhibition.
- The claims are structured to cover compounds, their use in therapy, and methods of synthesis.
- The patent sits within a competitive landscape of kinase inhibitor patents, with multiple family members and similar prior art.
- Legal uncertainties exist due to prior art references, potentially affecting claim validity.
- Enforceability may be challenged or limited by competing patents in the same domain.
Frequently Asked Questions
1. What is the scope of the chemical claims in EP2529621?
The claims cover benzamide derivatives with specific substitutions, aimed at kinase inhibition, with multiple substitution patterns described.
2. How broad are the use claims?
They specifically relate to using the compounds for treating cancers and inflammatory diseases, contingent on the chemical composition.
3. Are there notable similar patents in the landscape?
Yes, several patents filed within the same timeframe, particularly in the US and Asia, target similar kinase inhibitors.
4. What are the main risks of patent invalidity?
Prior art references for similar benzamide compounds and kinase inhibitors could be used to challenge the patent’s validity.
5. When does the patent expire?
Expected expiration is March 2032, assuming no extensions or pediatric data adjustments.
References
- European Patent Office. (2014). Patent EP2529621. Retrieved from [EPO database].
- WIPO. (2012). International Patent Application PCT/EP2012/063432.
- Patentscope. (2012). Family analysis for EP2529621.
- U.S. Patent and Trademark Office. (2016). Related US patent family members.
- ChemSpider. (2015). Benzamide derivatives in kinase inhibitor research.
